[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2000072800A3 - Il-8 receptor antagonists - Google Patents

Il-8 receptor antagonists Download PDF

Info

Publication number
WO2000072800A3
WO2000072800A3 PCT/US2000/014655 US0014655W WO0072800A3 WO 2000072800 A3 WO2000072800 A3 WO 2000072800A3 US 0014655 W US0014655 W US 0014655W WO 0072800 A3 WO0072800 A3 WO 0072800A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor antagonists
chemokine
interleukin
treatment
relates
Prior art date
Application number
PCT/US2000/014655
Other languages
French (fr)
Other versions
WO2000072800A2 (en
Inventor
Michael R Palovich
Katherine L Widdowson
Original Assignee
Smithkline Beecham Corp
Michael R Palovich
Katherine L Widdowson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Michael R Palovich, Katherine L Widdowson filed Critical Smithkline Beecham Corp
Publication of WO2000072800A2 publication Critical patent/WO2000072800A2/en
Publication of WO2000072800A3 publication Critical patent/WO2000072800A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention relates to the novel use of phenyl ureas in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
PCT/US2000/014655 1999-05-28 2000-05-26 Il-8 receptor antagonists WO2000072800A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13666699P 1999-05-28 1999-05-28
US60/136,666 1999-05-28

Publications (2)

Publication Number Publication Date
WO2000072800A2 WO2000072800A2 (en) 2000-12-07
WO2000072800A3 true WO2000072800A3 (en) 2001-03-08

Family

ID=22473834

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/014655 WO2000072800A2 (en) 1999-05-28 2000-05-26 Il-8 receptor antagonists

Country Status (1)

Country Link
WO (1) WO2000072800A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5170528A1 (en) * 1999-05-28 2002-06-27 Smithkline Beecham Corp ANTAGONISTS OF IL-8 RECEIVERS RECEIVERS OF IL-8
US6875759B1 (en) 1999-07-21 2005-04-05 Kadmus Pharmaceuticals Substituted guanidines and the use thereof
EP1413302A3 (en) * 1999-07-21 2004-05-12 Kadmus Pharmaceuticals, Inc. Substituted guanidines for the treatment of pain
WO2001007029A2 (en) * 1999-07-21 2001-02-01 Kadmus Pharmaceuticals, Inc. Substituted guanidines and the use thereof
AU2003303198A1 (en) 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
UA98456C2 (en) 2006-04-21 2012-05-25 Смитклайн Бичам Корпорейшн Il-8 receptor antagonists
US9926353B2 (en) 2011-07-19 2018-03-27 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
US8906382B2 (en) 2011-07-19 2014-12-09 New York University Method for treating amyloid disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709094A (en) * 1986-07-10 1987-11-24 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Sigma brain receptor ligands and their use
US5093525A (en) * 1986-07-10 1992-03-03 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709094A (en) * 1986-07-10 1987-11-24 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Sigma brain receptor ligands and their use
US5093525A (en) * 1986-07-10 1992-03-03 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists

Also Published As

Publication number Publication date
WO2000072800A2 (en) 2000-12-07

Similar Documents

Publication Publication Date Title
EP1357909A4 (en) Il-8 receptor antagonists
MXPA03006950A (en) 3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists.
TR200101772T2 (en) Hydroxy diphenyl urea sulfonamides as IL-8 Receptor antagonists
BR9612779A (en) Antagonists to the il-8 receptor
AP2004002982A0 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain.
EP1129089A4 (en) Spiro-indolines as y5 receptor antagonists
AP2002002605A0 (en) Il-8 receptor antagonists
TR199900318T2 (en) IL-8 receptor antagonists.
WO2007124423A3 (en) Il-8 receptor antagonists
WO2001068568A3 (en) Il-8 receptor antagonists
WO2005000231A3 (en) Il-8 receptor antagonists
WO2001068569A3 (en) Il-8 receptor antagonists
WO2001072960A3 (en) Il-8 receptor antagonists
NZ514696A (en) IL-8 receptor antagonists
WO2000072800A3 (en) Il-8 receptor antagonists
TR200103448T2 (en) IL-8 receptor antagonists.
WO2001064165A3 (en) Il-8 receptor antagonists
WO2001076530A3 (en) Il-8 receptor antagonists
WO2004039775A3 (en) Il-8 receptor antagonists
BR0010863A (en) Il-8 receptor antagonists
AP2002002606A0 (en) IL-8 receptor antagonists.
WO2001068033A3 (en) Il-8 receptor antagonists
WO2001068570A3 (en) Il-8 receptor antagonists
MXPA03000500A (en) Use of il-8 receptor antagonists in the treatment of virus infections.
NZ515232A (en) IL-8 receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP